316 related articles for article (PubMed ID: 28355984)
1. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases.
Bahloul E; Jallouli M; Garbaa S; Marzouk S; Masmoudi A; Turki H; Bahloul Z
Lupus; 2017 Oct; 26(12):1304-1308. PubMed ID: 28355984
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
[TBL] [Abstract][Full Text] [Related]
3. Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
Chacón-Dulcey V; López-Labady J; Villarroel-Dorrego M; Frías J; Tirado W; González N; Pérez Alfonzo R
Lupus; 2020 Jun; 29(7):761-766. PubMed ID: 32362181
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine.
Zhang S; Liu X; Cai L; Zhang J; Zhou C
Lupus; 2019 Jan; 28(1):129-132. PubMed ID: 30428763
[TBL] [Abstract][Full Text] [Related]
5. Hydroxycholoroquine-induced hyperpigmentation.
Mir A; Boyd KP; Meehan SA; McLellan B
Dermatol Online J; 2013 Dec; 19(12):20723. PubMed ID: 24365014
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine-induced hyperpigmentation.
Tracy CL; Blakey B; Parker G; Roebuck J
J Clin Rheumatol; 2013 Aug; 19(5):292. PubMed ID: 23884186
[No Abstract] [Full Text] [Related]
7. Woman in grey: hydroxychloroquine-induced hyperpigmentation.
Ivo R; Lopes CA; Reis R
BMJ Case Rep; 2018 Nov; 11(1):. PubMed ID: 30567137
[No Abstract] [Full Text] [Related]
8. Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Puri PK; Lountzis NI; Tyler W; Ferringer T
J Cutan Pathol; 2008 Dec; 35(12):1134-7. PubMed ID: 18727667
[TBL] [Abstract][Full Text] [Related]
9. Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.
Matsuda T; Ly NTM; Kambe N; Nguyen CTH; Ueda-Hayakawa I; Son Y; Okamoto H
J Dermatol; 2018 Mar; 45(3):344-348. PubMed ID: 29239026
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C; Moroni G
Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography.
Cabral RTS; Klumb EM; Couto MINN; Carneiro S
Arq Bras Oftalmol; 2019; 82(1):12-17. PubMed ID: 30403262
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine-induced erythroderma.
Pai SB; Sudershan B; Kuruvilla M; Kamath A; Suresh PK
Indian J Pharmacol; 2017; 49(1):132-134. PubMed ID: 28458440
[TBL] [Abstract][Full Text] [Related]
13. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
[TBL] [Abstract][Full Text] [Related]
14. Antimalarial cutaneous side effects: a study in 209 users.
Skare T; Ribeiro CF; Souza FH; Haendchen L; Jordão JM
Cutan Ocul Toxicol; 2011 Mar; 30(1):45-9. PubMed ID: 20950247
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine-induced pigmentation in two patients with systemic lupus erythematosus.
Reynaert S; Setterfield J; Black MM
J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):487-8. PubMed ID: 16643169
[No Abstract] [Full Text] [Related]
16. Generalized skin hyperpigmentation and longitudinal melanonychia secondary to treatment with hydroxychloroquine in systemic lupus erythematosus.
Sifuentes Giraldo WA; Grandal Platero M; de la Puente Bujidos C; Gámir Gámir ML
Reumatol Clin; 2013; 9(6):381-2. PubMed ID: 23481508
[No Abstract] [Full Text] [Related]
17. Evidence for risk of cardiomyopathy with hydroxychloroquine.
Sumpter MD; Tatro LS; Stoecker WV; Rader RK
Lupus; 2012 Dec; 21(14):1594-6. PubMed ID: 23036986
[No Abstract] [Full Text] [Related]
18. Cutaneous hyperpigmentation during therapy with hydroxychloroquine.
Amichai B; Gat A; Grunwald MH
J Clin Rheumatol; 2007 Apr; 13(2):113. PubMed ID: 17414546
[No Abstract] [Full Text] [Related]
19. [Skin pigmentation in a patient with systemic lupus erythematosus].
Jallouli M; Leroux G; Halabi-Tawil M; Morel N; Francès C; Piette JC; Amoura Z; Costedoat-Chalumeau N
Rev Med Interne; 2010 Aug; 31(8):566-7. PubMed ID: 20430486
[No Abstract] [Full Text] [Related]
20. Breastfeeding initiation, duration, and reasons for weaning in patients with systemic lupus erythematosus.
Acevedo M; Pretini J; Micelli M; Sequeira G; Kerzberg E
Rheumatol Int; 2017 Jul; 37(7):1183-1186. PubMed ID: 28540416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
